Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Precedex Approved for Long-Term Administration of over 24 Hours
September 6, 2010
- Takara Bio Begins Clinical Research for TCR Gene Therapy
September 6, 2010
- Genzyme Licenses Synvisc to Teijin Pharma
September 6, 2010
- Denosumab Applied for Bone Metastases: Daiichi Sankyo
September 6, 2010
- Towa to Expand Production Capacity with New Plant
September 6, 2010
- JCMOA to Be Kicked Off in October
September 6, 2010
- Banyu Files an NDA for Daptomycin
September 6, 2010
- Perampanel Shows Efficacy for Refractory Partial Seizure in PIII: Eisai
September 6, 2010
- Diovan Becomes Best-Selling Drug in April-June: IMS Japan
September 6, 2010
- Homeopathy Has No Scientific Grounds: SCJ
September 6, 2010
- Doctors Hope for Entry of Major Pharmas into Generics Market: Survey
September 6, 2010
- IBD Market to Grow to US$5.6 Bil. in 2019: Datamonitor
September 6, 2010
- Kyowa Kirin Withdraws Application for KW-2246
September 6, 2010
- Questionnaires on Use of Generics to Be Reconsidered
September 6, 2010
- JPMA Calls For Reduction in Effective Corporate Tax Rate to Int'l Standard
September 6, 2010
- PI Forum to Promote Drug Discovery: Chairman Asano
August 30, 2010
- Mebix's EDC Receives CDISC Certification
August 30, 2010
- Industry-Funded Trials More Likely to Publish Favorable Results: US Study
August 30, 2010
- JMA Expresses Concern about Commercial Use of Social Security Numbering System
August 30, 2010
- DSP Screens Candidates for Lurasidone's Successors
August 30, 2010
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…